All In Biotech

NDA 021470 · Leo Pharma As

Finacea

Azelaic Acid · Topical

Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 24, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

37

9 Phase 3, 1 recruiting

FAERS reports

841

445 serious, 84 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2021.

Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea ( 1 ). Limitations of Use Efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. ( 1 ) Limitations of Use Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

Mechanism: The mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FINACEA · AZELAIC ACID 15% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Azelaic Acid" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective154
  • pain131
  • off label use118
  • abdominal pain upper110
  • vomiting110
  • product use in unapproved indication103
  • gastrooesophageal reflux disease102
  • paraesthesia102
  • migraine101
  • memory impairment99
  • hypoaesthesia98
  • rash96

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20085
20093
20108
20112
20122
20133
20146
201520
201617
201712
201823
201931
202060
202167
202270
202385
2024134
2025139
2026150

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Finacea (Azelaic Acid)

2024 spending

$2.8M

Beneficiaries

3,256

6,032 claims

Per beneficiary

$852

$8.49 per unit

View as table
YearSpending
2020$1,569,425
2021$2,240,162
2022$2,310,123
2023$2,487,069
2024$2,773,453

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 108 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.